The Clinical Effect of Pregabalin on Neuropathic Pain in Non Central Sensitized Patients After Total Knee Arthroplasty
Primary Purpose
Osteoarthritis
Status
Not yet recruiting
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Pregabalin 150mg
Sponsored by
About this trial
This is an interventional treatment trial for Osteoarthritis focused on measuring Pregabalin, neuropathic pain
Eligibility Criteria
Inclusion Criteria:
- Patients for total knee arthroplasty over the age of 19
- Patients who have the will or ability to follow the doctor's instructions, including rehabilitation treatment such as joint exercise.
- Patients understand this study and agree in writing by the patient's own or by the patient's representative to participate in the study.
- Patients with non central sensitization and neuropathic pain.
Exclusion Criteria:
- Rheumatoid arthritis
- Other inflammatory arthritis
- Neuropsychiatric patients
- Hepatic insufficiency
- Renal insufficiency
- Allergy or intolerance to study medications
- Patients with an acetylsalicylic acid of IV (angina, congestive heart failure, dementia, cerebrovascular accident)
- Chronic gabapentin or pregabalin use (regular use for longer than 3 months)
- Chronic opioid use (taking opioids for longer than 3 months)
- Alcohol, drug abuser
- Narcotics addiction
Sites / Locations
- The Catholic Univerisity of Korea Seoul St Mary's hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Pregabalin
Active Comparator
Arm Description
Experimental group will take medicine for 10 weeks from 2 weeks before surgery to 8 weeks after surgery. The group takes one pill of pregabalin 150mg after breakfast and one pill of pregabalin 150 mg after dinner.
Active Comparator group will take no medicine
Outcomes
Primary Outcome Measures
Visual Pain Scale change
Visual pain scale is a validated questionnaire for evaluation of patients who underwent knee operation. The score range is 0-10. The lower the score, the better the result.
Secondary Outcome Measures
Western Ontario and McMaster University Arthritis Index Scale change
Western Ontario and McMaster University Arthritis Index (WOMAC) scale is a validated questionnarie for evaluation of patients who underwent knee operation. The questionnaire consists of 24 tiems, with five pain-related categories (score range 0-20), two stiffness categories (score range 0-8), and 17 physical functional categories (score range 0-68). All items were scored on a 5-point Likert scale (0 = none, 1 = slightly, 2 = moderate, 3 = serious, 4 = extreme). Total score range is 0-96. The lower the score, the better the result.
Knee range of motion change
Knee range of motion
Full Information
NCT ID
NCT05322681
First Posted
March 23, 2022
Last Updated
April 4, 2022
Sponsor
The Catholic University of Korea
1. Study Identification
Unique Protocol Identification Number
NCT05322681
Brief Title
The Clinical Effect of Pregabalin on Neuropathic Pain in Non Central Sensitized Patients After Total Knee Arthroplasty
Official Title
The Clinical Effect of Pregabalin on Neuropathic Pain in Non Central Sensitized Patients After Total Knee Arthroplasty: Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
May 2022 (Anticipated)
Primary Completion Date
May 2023 (Anticipated)
Study Completion Date
May 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Catholic University of Korea
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
In this study, patients scheduled to undergo total knee arthroplasty (TKA) will be screened through a survey for patients without central sensitivity and patients with neuropathic pain as preoperative evaluation.
It is designed to evaluate the effectiveness of pregabalin by dividing patient groups according to non central sensitization and neuropathic pain.
Detailed Description
Screening for central sensitization and neuropathic pain will be performed two weeks in advance of surgery for patients scheduled to undergo total knee arthroplasty, and is performed through a central sensitization questionnaire and neuropathic pain survey. Through the Central Sensitization Inventory, if the score is 40 or lower, it is considered as the subject of non central sensitization. And 13 or higher based on 38 points are considered as the subject of neuropathic pain.
Among the patients who meet these two criteria, only those who agree to the study are targeted. The same probability is assigned by a randomized table two weeks before surgery to a group taking pregabalin and a group taking no pill.
In the case of patients with non-central sensitization and neuropathic pain, the experimental group will take medicine for 10 weeks from 2 weeks before surgery to 8 weeks after surgery. The experimental group takes one pill of pregabalin 150mg after breakfast and one pill of pregabalin 150 mg after dinner. The control group takes no pill.
A total of 10 weeks' worth of drugs will be provided two weeks before surgery, and medication compliance will be evaluated based on the number of unused drugs returned by the test subject when the drug is returned. In order to evaluate medication compliance, clinical trials should record the number of drugs provided and returned at each visit and the discontinuation date. Subjects must receive medication guidance on the drug-taking schedule. When the clinical trial is completed or terminated in the middle, the unused or partially used drugs must be returned to the clinical examiner and discarded after confirmation.
Relief drugs can also be taken up to six tablets a day, up to two tablets of 650 mg of Tylenol ER Tablets(acetaminophen) once in both groups.
Anthropological information (gender, age, weight, height, body mass index) and outcome variables (VAS scale for checking the degree of pain) are analyzed for the subjects of the study among patients with neuropathic pain.
The subjects will be collected for three months after surgery in both the experimental group and the control group, and the data will be organized and the results will be derived after the last subject's three-month collection.
From immediately after surgery to three months after surgery, we will evaluate the side effects complaining in the subject group. Side effects will be evaluated through interviews with patients during outpatient visits. The above clinical evaluation is observed during the daily treatment process, and the method performed in this clinical trial is judged to have no unpredictable side effects during the current clinical process.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
Keywords
Pregabalin, neuropathic pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
90 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Pregabalin
Arm Type
Experimental
Arm Description
Experimental group will take medicine for 10 weeks from 2 weeks before surgery to 8 weeks after surgery. The group takes one pill of pregabalin 150mg after breakfast and one pill of pregabalin 150 mg after dinner.
Arm Title
Active Comparator
Arm Type
No Intervention
Arm Description
Active Comparator group will take no medicine
Intervention Type
Drug
Intervention Name(s)
Pregabalin 150mg
Other Intervention Name(s)
Lyrica 150mg
Intervention Description
Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
Primary Outcome Measure Information:
Title
Visual Pain Scale change
Description
Visual pain scale is a validated questionnaire for evaluation of patients who underwent knee operation. The score range is 0-10. The lower the score, the better the result.
Time Frame
Changes from preoperative Visual pain scale at postoperative 1,2,6,18 weeks and 1 year
Secondary Outcome Measure Information:
Title
Western Ontario and McMaster University Arthritis Index Scale change
Description
Western Ontario and McMaster University Arthritis Index (WOMAC) scale is a validated questionnarie for evaluation of patients who underwent knee operation. The questionnaire consists of 24 tiems, with five pain-related categories (score range 0-20), two stiffness categories (score range 0-8), and 17 physical functional categories (score range 0-68). All items were scored on a 5-point Likert scale (0 = none, 1 = slightly, 2 = moderate, 3 = serious, 4 = extreme). Total score range is 0-96. The lower the score, the better the result.
Time Frame
Changes from preoperative Western Ontario and McMaster University Arthritis Index (WOMAC) scale at postoperative 1, 2, 6, 18 weeks and 1 yea
Title
Knee range of motion change
Description
Knee range of motion
Time Frame
Changes from preoperative knee range of motion at postoperative 1, 2, 6, 18 weeks and 1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients for total knee arthroplasty over the age of 19
Patients who have the will or ability to follow the doctor's instructions, including rehabilitation treatment such as joint exercise.
Patients understand this study and agree in writing by the patient's own or by the patient's representative to participate in the study.
Patients with non central sensitization and neuropathic pain.
Exclusion Criteria:
Rheumatoid arthritis
Other inflammatory arthritis
Neuropsychiatric patients
Hepatic insufficiency
Renal insufficiency
Allergy or intolerance to study medications
Patients with an acetylsalicylic acid of IV (angina, congestive heart failure, dementia, cerebrovascular accident)
Chronic gabapentin or pregabalin use (regular use for longer than 3 months)
Chronic opioid use (taking opioids for longer than 3 months)
Alcohol, drug abuser
Narcotics addiction
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yong In, MD, PhD
Phone
82-10-9044-5228
Email
iy1000@catholic.ac.kr
First Name & Middle Initial & Last Name or Official Title & Degree
Mansoo Kim, MD
Phone
82-10-7233-3875
Email
kms3779@naver.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yong In, MD, PhD
Organizational Affiliation
The Catholic University of Korea
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Catholic Univerisity of Korea Seoul St Mary's hospital
City
Seoul
Country
Korea, Republic of
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ki Ho Kang, MD
Phone
82-10-7234-3188
Email
smilegiho@naver.com
First Name & Middle Initial & Last Name & Degree
Mansoo Kim, MD, PhD
Phone
82-10-7233-3875
Email
kms3779@naver.com
First Name & Middle Initial & Last Name & Degree
Yong In, MD, PhD
First Name & Middle Initial & Last Name & Degree
Mansoo Kim, MD, PhD
First Name & Middle Initial & Last Name & Degree
Jae Jung Kim, MD
First Name & Middle Initial & Last Name & Degree
Ki Ho Kang, MD
12. IPD Sharing Statement
Learn more about this trial
The Clinical Effect of Pregabalin on Neuropathic Pain in Non Central Sensitized Patients After Total Knee Arthroplasty
We'll reach out to this number within 24 hrs